Debt Free Direct
ADDDebt solutions group Debt Free Direct, first backed by GCI at 44.5p, has suffered serious recent share price reversals and the share price has come under pressure again despite significantly improved results for the year to the end of April.
Turnover rose an impressive 77% to £28m, while adjusted pre-tax profits doubled to £9.4m – a final dividend of 3p made for total dividends of 6p. Chief executive Andrew Redmond flagged up a turbulent financial year in which Debt Free Direct saw the demise of a number of its creditors. The group itself suffered from increased competition, creditor reluctance to accept IVAs (Individual Voluntary Arrangements) and consumer unease.
Run rates of new IVAs in the current year are so far in line with the second half of last year, though Redmond argues Debt Free Direct is well positioned to build volumes again, thanks to an improving share of the IVA advertising space and signs of renewed understanding among creditors. Consolidation in the debt advice/IVA sector is starting to take place, and Debt Free Direct is playing its part, having just acquired Clear Start UK for £11m. This fast-growing consumer debt advice business recorded a pre-tax loss of £1.4m on turnover of £4m in the year to 31 March.
Pre-Clear Start, analysts were looking for earnings of between 24.1p and 25.5p for this year, rising to between 32p and 38.2p for 2009. Based on those numbers, Debt Free Direct trades on a forward p/e of only 10 times and looks substantially undervalued.
- Reduce text size Decrease text size
- Increase text size Increase text size
- Print article Print
- Share this article Share
- Email article to a friend Email
Market cap: £89.6m
PE Forecast: 10
Share price: 238.25p
Subscribe today
More breaking news stories.
More extended feature articles.
And a depth of analysis you
can't find anywhere else.
Advertisement
VCT Report 2010
VCT Report 2010 uncovers the money available
for investment in every single VCT, helping you get one step ahead in the race to attract funding for your unquoted, AIM-listed or PLUS-quoted
company.
Order VCT Report 2010 today using this online form
Cash Shells Directory 2010
A comprehensive overview of cash shells on AIM and PLUS, companies that have become a significant feature on the market landscape. For more information and to order, click here or contact our marketing team on 020 7250 7056.
Coverage of AIM, techMARK and PLUS Markets
Informative features and research on fast-growing companies, small-cap and growth stocks, penny shares, stock market tips and share recommendations, directors' dealings, company news and analysis, new issues and upcoming IPOs.
Take control of your investments
A full year's subscription to What Investment magazine for £19.95, a whopping 58% off. Get the latest news, features and expert advice on ISAs, Investment Trusts and Funds, SIPPS, Investing for Children and much much
more. Find out more here.
The Financial Times Guide to Personal Tax
is the definitive and most up-to-date guide to completing your self-assessment tax return, making sure that you get it right and on time, and showing how you can save tax. For more information and to order, click here or contact our marketing team on 020 7250 7056.
The AIM Guide Spring 2010
The new, fully updated AIM Guide is now available to buy for only £49.95 (saving you £30).
A 'must-have' for any serious investor or professional interested in the market for young, fast-growing companies. Order your copy today Hurry, as offer ends soon!
Share recommendations and small-cap stock picks
Small-cap and growth company share recommendations on AIM- and PLUS-listed companies. Latest analysts' stock tips and advice on which are the best shares to buy on London's junior stock markets.
Popular Recommendations
Advertisement
Latest Recommendations
Delcam 01/09/2010
Delcam, the international seller of CAD/CAM software to the engineering, aerospace and healthcare sectors among others, is a cash-generative small-cap seeing recovery in its markets.
Antisoma 01/09/2010
Bombed-out biotech play Antisoma is hoping two of its drugs will lead to good fortune after experiencing disaster with lung cancer treatment ASA404.
GW Pharmaceuticals 31/08/2010
GW Pharmaceuticals has won approval from Health Canada for its cannabis-based Sativex product to treat spasticity caused by Multiple Sclerosis.
Sectors
